Showing results (431-440 of 661) with videos related to
Sort By:
Pageof 67
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancerMohamed Kabbout, Melinda M Garcia, Junya Fujimoto, et al.Cancer Prevention Research (Philadelphia, Pa.)|April 25, 2022
Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the LungMaya Hassane, Zahraa Rahal, Nareg Karaoghlanian, et al.Oncotarget|December 17, 2016
The ISG15-specific protease USP18 regulates stability of PTENLisa Maria Mustachio, Masanori Kawakami, Yun Lu, et al.Cancer|November 18, 2025
Chemotherapy alone for stage II-IVa laryngeal squamous cell carcinoma: A 20-year follow-upMateus Trinconi Cunha, Matheus Sewastjanow-Silva, F Christopher Holsinger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neckAnne S Tsao, Adam S Garden, Merrill S Kies, et al.Journal of the National Cancer Institute|February 6, 2003
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancerJulie G Izzo, Vassiliki A Papadimitrakopoulou, Diane D Liu, et al.Molecular Cancer Therapeutics|March 22, 2013
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal diseaseLai-Ping Zhong, Dong-Wang Zhu, William N William, et al.Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyErick Riquelme, Milind Suraokar, Carmen Behrens, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapyApar Pataer, Neda Kalhor, Arlene M Correa, et al.Pageof 67